Bradykinin-potentiating peptides: beyond captopril.

Toxicon : official journal of the International Society on Toxinology (2011-08-13)
Antonio C M Camargo, Danielle Ianzer, Juliano R Guerreiro, Solange M T Serrano

The identification of novel endogenous and exogenous molecules acting in the complex mechanism of regulating the vascular tonus has always been of great interest. The discovery of bradykinin (1949) and the bradykinin-potentiating peptides (1965) had a pivotal influence in the field, respectively, in understanding cardiovascular pathophysiology and in the development of captopril, the first active-site directed inhibitor of angiotensin-converting enzyme, and used worldwide to treat human hypertension. Both discoveries originated from studies of envenoming by the snake Bothrops jararaca. The aim of the present article is to reveal that the snake proline-rich oligopeptides, known as bradykinin-potentiating peptides, are still a source of surprising scientific discoveries, some of them useful not only to reveal potential new targets but also to introduce prospective lead molecules for drug development. In particular, we emphasize argininosuccinate synthetase as a new functional target for one of bradykinin-potentiating peptides found in B. jararaca, Bj-BPP-10c. This decapeptide leads to argininosuccinate synthetase activation, consequently sustaining increased nitric oxide production, a critical endogenous molecule to reduce the arterial blood pressure.

Product Number
Product Description

Captopril for system suitability, European Pharmacopoeia (EP) Reference Standard
Captopril, European Pharmacopoeia (EP) Reference Standard
Captopril, meets USP testing specifications
Captopril, ≥98% (HPLC), powder
Captopril, United States Pharmacopeia (USP) Reference Standard
Captopril, Pharmaceutical Secondary Standard; Certified Reference Material